As proof-of-principle, both zebrafish embryos and adults carrying FLT3ITDIDH2R172K and FLT3ITDIDH2R140Q mutations responded to quizartinib/gilteritinib, and enasidenib, which were effective agents for FLT3ITD [34, 35] and IDH2 mutant AML [36, 37]. This evidence concerns the gene IDH2 and acute myeloid leukemia.